🤯 Have you seen our AI stock pickers’ 2024 results? 84.62%! Grab November’s list now.Pick Stocks with AI

Merck To Buy Private Cancer Drugmaker Peloton Therapeutics

Published 05/21/2019, 09:37 PM
Updated 07/09/2023, 06:31 AM
US500
-
LLY
-
MRK
-
CELG
-
BMY
-
EXEL
-

Merck & Co., Inc. (NYSE:MRK) announced a definitive agreement to buy small private cancer biotech, Peloton Therapeutics for an upfront payment of $1.05 billion in cash. The acquisition will add Peloton’s novel late-stage renal cell carcinoma (RCC) candidate, PT2977 to Merck’s oncology pipeline, which is currently riding on the success of its blockbuster PD-L1 inhibitor Keytruda.

PT2977, an oral HIF-2α inhibitor, is currently being evaluated in multiple cancer studies including phase II studies in von Hippel-Lindau (VHL) disease-associated RCC and in combination with Exelixis, Inc.’s (NASDAQ:EXEL) Cabometyx (cabozantinib) , a VEGFR-targeting agent, in metastatic RCC and a phase I/II study in metastatic RCC.

In addition to the upfront payment, Merck will also be entitled to pay a further $1.15 billion of potential milestones payments. The transaction is expected to close in the third quarter of 2019.

This is Merck’s second acquisition of cancer-focused biotech this year. In April, Merck closed its previously announced acquisition of small cancer focused biotech, Immune Designfor an approximate value of $300 million.

Merck’s stock has risen 4% this year so far against the industry’s decline of 1.3%.

This year has been good as far as M&A activity in the pharmaceuticals/biotech industry is concerned. Oncology and immuno-oncology are key areas of focus. Bristol-Myers Squibb Co. (NYSE:BMY) , one of the largest pharma giants, announced that it will acquire leading biotech company Celgene (NASDAQ:CELG) for a whopping $74 billion. This will be one of the largest acquisitions in recent times.

Another large-cap pharma company Eli Lilly (NYSE:LLY) bought Loxo Oncology in February for $8.0 billion to broaden its oncology portfolio. Roche also announced an agreement to acquire Spark Therapeutics in February 2019 for $4.8 billion. Post completion of the buyout, Roche will get access to Spark Therapeutics’ novel gene therapy, SPK-8011 for the treatment of hemophilia A, which is expected to enter phase III in 2019

A surge in M&A activity during 2019 is expected in the overall drug/biotech sector on the lines of Bristol-Myers and Eli Lilly as companies look to use huge cash reserve and combat rivalry woes.

Merck currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.

This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.

See their latest picks free >>



Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report

Merck & Co., Inc. (MRK): Free Stock Analysis Report

Eli Lilly and Company (LLY): Free Stock Analysis Report

Exelixis, Inc. (EXEL): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.